PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ERα serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive, HER2-negative early breast cancer

被引：0
|
作者：
Ishida, Naoko
Hatanaka, Yutaka
Baba, Motoi
Hagio, Kanako
Okada, Hiromi
Hatanaka, Kanako C.
Matsuno, Yoshihiro
Yamashita, Hiroko
机构：
[1] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[2] Hokkaido Univ Hosp, Res Div Compan Diagnost, Sapporo, Hokkaido, Japan
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-08-07
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Low phosphorylation of estrogen receptor a (ERα) serine 118 and high phosphorylation of ERα serine 167 improve survival in ER-positive breast cancer
    Yamashita, Hiroko
    Nishio, Mariko
    Toyama, Tatsuya
    Sugiura, Hiroshi
    Kondo, Naoto
    Kobayashi, Shunzo
    Fujii, Yoshitaka
    Iwase, Hirotaka
    [J]. ENDOCRINE-RELATED CANCER, 2008, 15 (03) : 755 - 763
  • [2] PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Fusco, Nicola
    Malapelle, Umberto
    Fassan, Matteo
    Marchio, Caterina
    Buglioni, Simonetta
    Zupo, Simonetta
    Criscitiello, Carmen
    Vigneri, Paolo
    Dei Tos, Angelo Paolo
    Maiorano, Eugenio
    Viale, Giuseppe
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [3] Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer
    Leenhardt, Fanny
    Alexandre, Marie
    Jacot, William
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (06) : 667 - 675
  • [4] The somatic mutation profile of estrogen receptor-positive HER2-negative metastatic breast cancer in Brazilian patients
    Reinert, Tomas
    do Rego, Fernanda Orpinelli
    Silva, Matheus Costa e
    Rodrigues, Amanda Muniz
    Koyama, Fernanda Christtanini
    Goncalves, Aline Coelho
    Pauletto, Maiane Maria
    de Carvalho Oliveira, Leandro Jonata
    de Resende, Cristiano Augusto Andrade
    Landeiro, Luciana Castro Garcia
    Barrios, Carlos Henrique
    Mano, Max Senna
    Dienstmann, Rodrigo
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [5] Clinical considerations for estrogen receptor-negative/ progesterone receptor-positive/HER2-negative (ER-PR+HER2-) breast cancer
    Rala de Paula, Bruno Henrique
    Crocamo, Susanne
    Bines, Jose
    [J]. TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [6] FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    Charlab, Rosane
    Chen, Wei
    Palmby, Todd
    Tilley, Amy
    Zirkelbach, Jeanne Fourie
    Yu, Jingyu
    Liu, Qi
    Zhao, Liang
    Crich, Joyce
    Chen, Xiao Hong
    Hughes, Minerva
    Bloomquist, Erik
    Tang, Shenghui
    Sridhara, Rajeshwari
    Kluetz, Paul G.
    Kim, Geoffrey
    Ibrahim, Amna
    Pazdur, Richard
    Cortazar, Patricia
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4760 - 4766
  • [7] High phosphorylation of estrogen receptor α serine 167 and low p53 protein accumulation improve survival in estrogen receptor-positive breast cancer patients treated with tamoxifen
    Sugiura, H.
    Toyama, T.
    Kondo, N.
    Kobayashi, S.
    Fujii, Y.
    Yamashita, H.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S243 - S243
  • [8] Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer
    Hiroko Yamashita
    Akiko Ogiya
    Tadahiko Shien
    Yoshiya Horimoto
    Norikazu Masuda
    Touko Inao
    Tomofumi Osako
    Masato Takahashi
    Yumi Endo
    Mitsuchika Hosoda
    Naoko Ishida
    Rie Horii
    Kieko Yamazaki
    Yuichiro Miyoshi
    Hiroyuki Yasojima
    Nobumoto Tomioka
    [J]. Breast Cancer, 2016, 23 : 830 - 843
  • [9] Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer
    Yamashita, Hiroko
    Ogiya, Akiko
    Shien, Tadahiko
    Horimoto, Yoshiya
    Masuda, Norikazu
    Inao, Touko
    Osako, Tomofumi
    Takahashi, Masato
    Endo, Yumi
    Hosoda, Mitsuchika
    Ishida, Naoko
    Horii, Rie
    Yamazaki, Kieko
    Miyoshi, Yuichiro
    Yasojima, Hiroyuki
    Tomioka, Nobumoto
    [J]. BREAST CANCER, 2016, 23 (06) : 830 - 843
  • [10] PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories
    Pepe, Francesco
    Venetis, Konstantinos
    Cursano, Giulia
    Frascarelli, Chiara
    Pisapia, Pasquale
    Vacirca, Davide
    Scimone, Claudia
    Rappa, Alessandra
    Russo, Gianluca
    Mane, Eltjona
    Pagni, Fabio
    Castellano, Isabella
    Troncone, Giancarlo
    Angelis, Carmine De
    Curigliano, Giuseppe
    Guerini-Rocco, Elena
    Malapelle, Umberto
    Fusco, Nicola
    [J]. PHARMACOGENOMICS, 2024, 25 (03) : 161 - 169
12345